Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12434390 | 0.89 | ALOX5 (0.59) | ALOX5ALDH1A1HPGDSMN1; SMN2HDAC3 | |
| SCHEMBL10658522 | 0.88 | HPGD (0.69) | MAPK1ALDH1A1HPGDSMN1; SMN2HDAC3 | |
| SCHEMBL13293977 | 0.88 | HPGD (0.69) | MAPK1ALDH1A1HPGDSMN1; SMN2HDAC3 | |
| SCHEMBL5657646 | 0.85 | ALOX5 (0.82) | ALOX5MAPK1ALDH1A1HPGDLMNA | |
| SCHEMBL16771620 | 0.85 | ALOX5 (0.62) | ALOX5ALDH1A1HPGDSMN1; SMN2HDAC3 | |
| SCHEMBL8670660 | 0.85 | ALOX5 (0.82) | ALOX5MAPK1ALDH1A1HPGDLMNA | |
| SCHEMBL21579680 | 0.84 | ALOX5 (0.79) | ALOX5MAPK1ALDH1A1HPGDLMNA | |
| SCHEMBL4408502 | 0.83 | ALOX5 (0.59) | ALOX5MAPK1ALDH1A1HPGDLMNA | |
| SCHEMBL11335758 | 0.82 | HPGD (0.70) | ALDH1A1HPGDSMN1; SMN2HDAC3NR1H4 | |
| SCHEMBL13593340 | 0.81 | NAAA (0.70) | ALOX5MAPK1ALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| WO-1998034632-A9 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 1999-09-02 | — | — | WO | claimed |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | LE ROUX DANIELLE MARIE (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| EP-2409569-B1 | Method for administering GLP-1 molecules | EMISPHERE TECH INC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| EP-1478233-B1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECH INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-11-19 | — | — | US | disclosed |
| US-7553872-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553872-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7071214-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-5962710-A | Method of preparing salicyloylamino acids | EMISPHERE TECHNOLOGIES, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1998034632-A9 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 1999-09-02 | — | — | WO | disclosed |
| US-5858995-A | ADMINISTERING TO HUMANS AND ANIMALS IN THE TREATMENT OF DISEASES CAUSED BY ABNORMAL BONE METABOLISM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-01-12 | — | — | US | disclosed |
| WO-1998050341-A1 | METHOD OF PREPARING SALICYLOYLAMINO ACIDS | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | ALOX5 2377/4885MAPK1 1670/4885ALDH1A1 3386/4885 |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | VIP, GIPR, SLC10A2 | ALOX5 1498/4885MAPK1 2609/4885ALDH1A1 4359/4885 |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | ALOX5 2377/4885MAPK1 1670/4885ALDH1A1 3386/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | ALOX5 203/4885MAPK1 3137/4885ALDH1A1 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.